argenx publishes positive results from efgartigimod Phase 2 ITP trial
Category: #health  By Mateen Dalal  Date: 2019-12-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

argenx publishes positive results from efgartigimod Phase 2 ITP trial

argenx, a renowned Netherlands based biotechnology firm, reportedly announced the publication of outcomes from the assessment of its FcRn antagonist, efgartigimod, in a Phase 2 ITP clinical trial, in the American Journal of Hematology.

Wim Parys, M.D., chief medical officer, argenx, reportedly stated that efgartigimod showcased a favorable tolerability and the capability to drive encouraging response rates across a refractory demographic after a limited exposure. Parys further added that the company is thrilled to announce the publication of efgartigimod Phase 2 ITP trial results as a new treatment modality in ITP. The company is now looking forward towards advancing efgartigimod into a global Phase 3 ITP program before 2019 ends, where the company would get the opportunity to dose participants in a long-term setting.

The global Phase 3 program in ITP remains on track to start this month and would assess the intravenous (IV) formulation inside the first clinical trial, ADVANCE, along with an IV induction that would be followed by a SC (subcutaneous) maintenance injection in the second trial, ADVANCE SC.

Additionally, efgartigimod is also presently being evaluated for the treatment of serious autoimmune diseases, including chronic inflammatory demyelinating polyneuropathy (CIDP), generalized myasthenia gravis (gMG) and pemphigus vulgaris (PV).

The ADAPT Phase 3 trial of IV efgartigimod in gMG is in progress with data expected in the last two quarters of 2020. A Phase 2 PoC (proof-of-concept) is also in progress in PV and data is expected in the first two quarters of 2020. Meanwhile, a Phase 2 PoC (proof-of-concept) trial of efgartigimod SC in CIDP is expected to start before the end of 2019.

About argenx:

argenx, is a renowned biopharmaceutical firm. It develops and creates a pipeline of differentiated anti-body therapeutics using its Simple Antibody platform, which is based on the powerful llama immune system. The firm develops a deep pipeline of anti-body therapeutics that focuses on cancer and auto-immune diseases.

It creates antibodies that have the best in class therapeutic potential. It includes: ARGX-111, an antagonist of c-Met; a receptor involved in cell proliferation, metastasis and angiogenesis in multiple solid tumors; ARGX-112, an antigen targeting atopic dermatitis, among others.
 

Source credit: https://www.argenx.com/en-GB/news-internal/argenx-announces-publication-of-efgartigimod-phase-2-primary-immune-thrombocytopenia-trial-results-in-american-journal-of-hematology/30242/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Microsoft investigates Teams and Outlook outage that left users disrupted
Microsoft investigates Teams and Outlook outage that left users disrupted
By Mateen Dalal

Microsoft, the U.S.-based technology frontrunner, reportedly investigating an outage that prevented thousands of customers from accessing services like Teams and Outlook. Apparently, the tech giant did not disclose the number of users that were im...

DeHaat secures $60 million in funding, tops $700 million valuation
DeHaat secures $60 million in funding, tops $700 million valuation
By Mateen Dalal

Indian agritech firm DeHaat has reportedly raised $60 million in a new funding round as it looks forward to strengthening its footprint in the country and touching break-even profitability in two years. For the unversed, the startup provides a range ...

Sensorium registers new branch in UAE to expand global presence
Sensorium registers new branch in UAE to expand global presence
By Mateen Dalal

Sensorium, developer of the Sensorium Galaxy metaverse, has registered its new branch in the United Arab Emirates (UAE) as Dubai gradually becomes a global hub for metaverse companies. The new entity, slated to be officially inaugurated in the com...